Liontos, Michalis <br/><br/>
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.  [electronic resource] 

 -  World journal of urology  Mar 2017 
 - 411-419 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1433-8726 
<br/><br/><label>Standard No.: </label>10.1007/s00345-016-1890-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adaptor Proteins, Signal Transducing--metabolism<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Cell Cycle Proteins<br/>Class Ia Phosphatidylinositol 3-Kinase<br/>Class Ib Phosphatidylinositol 3-Kinase--metabolism<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Indoles--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>PTEN Phosphohydrolase--metabolism<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Phosphoproteins--metabolism<br/>Prognosis<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Pyrroles--therapeutic use<br/>Retrospective Studies<br/>Ribosomal Protein S6 Kinases, 70-kDa--metabolism<br/>Sunitinib<br/>Survival Rate<br/>TOR Serine-Threonine Kinases--metabolism<br/>Vascular Endothelial Growth Factor A--metabolism